Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) Director Michael Hayden bought 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $51.60 per share, for a total transaction of $258,000.00. Following the completion of the acquisition, the director directly owned 24,000 shares in the company, valued at $1,238,400. The trade was a 26.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ionis Pharmaceuticals Stock Performance
Ionis Pharmaceuticals stock opened at $51.77 on Friday. The firm has a 50 day simple moving average of $69.55 and a 200-day simple moving average of $74.57. The stock has a market cap of $8.56 billion, a price-to-earnings ratio of -14.96 and a beta of 0.36. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 4.09. Ionis Pharmaceuticals, Inc. has a 1-year low of $40.03 and a 1-year high of $86.74.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative net margin of 64.76% and a negative return on equity of 111.08%. The firm had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.56 million. During the same quarter in the previous year, the company earned ($0.93) EPS. The business's revenue for the quarter was up 86.4% compared to the same quarter last year. On average, analysts expect that Ionis Pharmaceuticals, Inc. will post -3.69 EPS for the current year.
Institutional Trading of Ionis Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB lifted its position in shares of Ionis Pharmaceuticals by 79.1% during the second quarter. Handelsbanken Fonder AB now owns 383,211 shares of the company's stock worth $30,385,000 after purchasing an additional 169,300 shares in the last quarter. Victrix Investment Advisors acquired a new position in shares of Ionis Pharmaceuticals in the second quarter valued at approximately $270,000. Assenagon Asset Management S.A. grew its holdings in shares of Ionis Pharmaceuticals by 21.5% in the second quarter. Assenagon Asset Management S.A. now owns 40,927 shares of the company's stock valued at $3,245,000 after purchasing an additional 7,254 shares in the last quarter. GAMMA Investing LLC increased its stake in Ionis Pharmaceuticals by 22.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,168 shares of the company's stock worth $172,000 after buying an additional 402 shares during the period. Finally, Harbor Investment Advisory LLC purchased a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $112,000. Institutional investors and hedge funds own 93.86% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. Guggenheim reduced their target price on Ionis Pharmaceuticals from $106.00 to $89.00 and set a "buy" rating on the stock in a research report on Tuesday, July 21st. Oppenheimer reaffirmed an "outperform" rating and issued a $111.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, April 30th. Leerink Partners increased their price target on Ionis Pharmaceuticals from $122.00 to $129.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. TD Cowen reissued a "buy" rating and set a $108.00 price objective on shares of Ionis Pharmaceuticals in a research report on Monday, June 15th. Finally, Bank of America boosted their price objective on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a "buy" rating in a report on Thursday, April 9th. Eighteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $94.85.
Read Our Latest Stock Report on Ionis Pharmaceuticals
Key Ionis Pharmaceuticals News
Here are the key news stories impacting Ionis Pharmaceuticals this week:
- Positive Sentiment: Ionis beat Wall Street’s second-quarter revenue and earnings expectations, helped by commercial growth despite difficult year-over-year comparisons. Management also reaffirmed its 2026 outlook, supporting confidence in the company’s operating trajectory. Zacks Q2 earnings report
- Positive Sentiment: Director Michael R. Hayden bought 15,000 shares for approximately $800,700 on July 30 and another 5,000 shares for $258,000 on July 31. The purchases materially increased his ownership and may be viewed as a signal of confidence in Ionis’s valuation and prospects. SEC insider-trading filing
- Neutral Sentiment: Wells Fargo lowered its price target from $100 to $95 while maintaining an “overweight” rating. The reduced target reflects more cautious valuation expectations, but the rating remains bullish. Benzinga analyst report
- Neutral Sentiment: HC Wainwright cut its target from $125 to $115 but retained a “buy” rating, similarly indicating lower near-term valuation expectations while maintaining a positive view of the stock. StreetInsider analyst report
- Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Ionis investors. Although the announcement does not establish wrongdoing, it adds legal and reputational uncertainty and may weigh on sentiment. Pomerantz investor alert
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
